Cancer stem cells (CSCs), also called tumor-initiating cells (TICs), have been studied intensively due to their rapid proliferation, migration, and role in the recurrence of cancer. In general, CSC marker-positive cells [CD133, CD44, CD166, aldehyde dehydrogenase (ALDH), and epithelial cell adhesion molecule (EpCAM)] exhibit a 100-fold increased capacity to initiate cancer. Within a heterogeneous tumor mass, only approximately 0.05-3% of cells are suspected to be CSCs and able to proliferate under hypoxia. Interestingly, CSCs, cancer cells, and normal stem cells share many cytochemical properties, such as inhibition of the redox system for reactive oxygen species (ROS) production and high expression of drug resistance transporters. However, compared to normal stem cells, CSCs develop unique metabolic flexibility, which involves switching between oxidative phosphorylation (OXPHOS) and glycolysis as their main source of energy. Due to the similarities between CSCs and other cancer cells and normal stem cells, limited chemotherapeutic and bio-imaging reagents specific for CSCs have been developed. In this short review, we address the current knowledge regarding CSCs with a focus on designing chemotherapeutic and bio-imaging reagents that target CSCs.
Bibliographical noteFunding Information:
This work was supported by the CRI project (grant no. 2018R1A3B1052702 to J. S. K.), the Basic Science Research Programs (grant no. 2018R1A2B6002275 to J. H. and 2017R1D1A1B03030062 to M. W.) and the global PhD fellowship (GPF) program (2019H1A2A1074096, J. H. K.) of the National Research Foundation of Korea (NRF), funded by the Ministry of Education. We also gratefully acknowledge support from Korea University and Hyupsung University.
© The Royal Society of Chemistry.
ASJC Scopus subject areas